Showing 3281-3290 of 5621 results for "".
- Commentary: Endothelial Cell Density After Iris-Fixated Phakic IOLhttps://modernod.com/news/endothelial-cell-density-after-iris-fixated-phakic-iol/2479908/There are three main types of phakic intraocular lenses (pIOL): those secured in the anterior chamber angle, those secured to the iris, and those placed between the crystalline lens and the iris. The latter two types are approved by the US Food and Drug Administration for use in the United States
- Roche’s Genentech Unit to Cut 223 Jobs in UShttps://modernod.com/news/roches-genentech-unit-to-cut-223-jobs-in-us/2479930/Roche’s Genentech unit plans to cut 223 jobs from its South San Francisco, California headquarters by the end of the year. The company, which disclosed the staff reductions in a Worker Adjustment and Retraining Notification (WARN) posted by the State of California’s Employment Develop
- FDA Approves 12-Week Dosing for Eylea in Wet AMD Patientshttps://modernod.com/news/fda-approves-12-week-dosing-for-eylea-in-wet-amd-patients/2479932/Regeneron announced that the FDA has approved a supplemental Biologics License Application for Eylea (aflibercept) injection in patients with wet age-related macular degeneration (AMD). The application was based on second-year data from the phase 3 VIEW 1 and 2 trials in which patients with wet A
- Breakthrough in AI Technology to Improve Care for Patientshttps://modernod.com/news/breakthrough-in-ai-technology-to-improve-care-for-patients/2479943/Two years ago, Moorfields Eye Hospital NHS Foundation Trust and DeepMind Health came together to announce a 5-year partnership to explore whether artificial intelligence (AI) technology could help clinicians improve care for patients. Researchers from Moorfields and the UCL Institute of Op
- Regeneron Faces Delay to FDA Approval of 12-Week Dosing Schedule for Eylea in Wet AMDhttps://modernod.com/news/regeneron-faces-delay-to-fda-approval-of-12-week-dosing-schedule-for-eylea-in-wet-amd/2479946/Regeneron announced that the FDA issued a complete response letter regarding a filing seeking approval of a 12-week dosing schedule for »Eylea (aflibercept) in patients wit
- Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates IOP Lowering and Patient Usabilityhttps://modernod.com/news/eyenovias-eyn-pg21-trial-evaluating-high-precision-microdose-of-latanoprost-demonstrates-iop-lowering-and-patient-usability/2479947/Eyenovia announced positive results of its EYN PG21 proof-of-concept study of microdose latanoprost for the lowering of IOP and patient usability. The EYN PG21 clinical study investigated the medication administration effectiveness and IOP lowering effect of
- Gene Mutation Found in Aqueous Humor May Detect Vitreoretinal Lymphomahttps://modernod.com/news/gene-mutation-found-in-aqueous-humor-may-detect-vitreoretinal-lymphoma/2479958/Ultrasensitive droplet digital polymerase chain reaction (ddPCR) is a potential new biopsy tool to diagnose and monitor vitreoretinal lymphoma (VRL), new research from the Netherlands suggests, according to a
- Ocutech Introduces New Ves Falcon Autofocus Bioptic Telescopehttps://modernod.com/news/ocutech-introduces-new-ves-falcon-autofocus-bioptic-telescope/2479963/Following 6 years of development and testing, Ocutech has introduced its new VES Falcon Autofocus Bioptic Telescope, the company’s next generation autofocusing bioptic for the visually impaired. The Falcon is in initial limited release with select low-vision specialists in the United
- A Daily Orange May Reduce AMD Risk, Study Findshttps://modernod.com/news/a-daily-orange-may-reduce-amd-risk-study-finds/2479986/People who consume at least one orange per day have a 60% lower risk of developing age-related macular degeneration (AMD) 15 years later compared with those who do not eat oranges, a study has found, according to a report in Medscape.
- Q Biomed Extends its Exclusive Option Agreement With Washington University for Glaucoma Detection Biomarkerhttps://modernod.com/news/q-biomed-extends-its-exclusive-option-agreement-with-washington-university-for-glaucoma-detection-biomarker/2479989/Q BioMed has announced that it is extending its option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will continue to evaluate the feasibility and